Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1373 ARTÍCULOS , VIENDO DEL 1021 AL 1035

Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI

Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, Senjem ML, Jordan L, Jack CR Jr, Knopman D, Petersen RC.

Neurology. 2013 Jun 4;80(23):2130-7. doi: 10.1212/WNL.0b013e318295d6cf. Epub 2013 May 3.

Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study

Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Verhey FR, Winblad B, Wahlund LO, Wilcock G, Visser PJ.

Dement Geriatr Cogn Disord. 2013;36(1-2):1-19. doi: 10.1159/000348354. Epub 2013 May 3.

Mild cognitive impairment due to Alzheimer disease in the community

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR Jr.

Ann Neurol. 2013 Aug;74(2):199-208. doi: 10.1002/ana.23931.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.

Ushering in the study and treatment of preclinical Alzheimer disease

Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM.

Nat Rev Neurol. 2013 Jul;9(7):371-81. doi: 10.1038/nrneurol.2013.107. Epub 2013 Jun 11.

Inflammatory proteins in plasma are associated with severity of Alzheimer's disease

Leung R, Proitsi P, Simmons A, Lunnon K, Güntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund LO, Lovestone S.

PLoS One. 2013 Jun 10;8(6):e64971. doi: 10.1371/journal.pone.0064971. Print 2013.

Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism

Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

JAMA Neurol. 2013 Aug;70(8):1039-45. doi: 10.1001/jamaneurol.2013.1878.

Diffusion tensor imaging measures of normal appearing white matter in patients who are aging, or have amnestic mild cognitive impairment, or Alzheimer's disease

Wang JH, Lv PY, Wang HB, Li ZL, Li N, Sun ZY, Zhao BH, Huang Y.

J Clin Neurosci. 2013 Aug;20(8):1089-94. doi: 10.1016/j.jocn.2012.09.025. Epub 2013 Jun 17.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease

Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K.

PLoS One. 2013 Jun 14;8(6):e66381. doi: 10.1371/journal.pone.0066381. Print 2013.

Fluid biomarkers in Alzheimer's disease - current concepts

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20.

2013 Alzheimer Award

J Alzheimers Dis. 2013;36(3):413-4. doi: 10.3233/JAD-139903.

Is there a causal link between inflammation and dementia?

Enciu AM, Popescu BO.

Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias